Gelteq Limited Ordinary Shares (GELS)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
GELS
Gelteq Limited Ordinary Shares
$0.57
-1.67%
HEALTHCARE · Cap: $5.97M
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.03
-1.10%
HEALTHCARE · Cap: $58.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 979002616% more annual revenue ($4.62T vs $471,800). GELS leads profitability with a 0.0% profit margin vs -3.5%. TAK earns a higher WallStSmart Score of 53/100 (C-).
GELS
Avoid33
out of 100
Grade: F
TAK
Buy53
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 48.9% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : GELS
The strongest argument for GELS centers on Price/Book, Revenue Growth. Revenue growth of 48.9% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bear Case : GELS
The primary concerns for GELS are EPS Growth, Market Cap, Profit Margin.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
GELS profiles as a hypergrowth stock while TAK is a turnaround play — different risk/reward profiles.
GELS is growing revenue faster at 48.9% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (53/100 vs 33/100) and 10.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gelteq Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. The company is headquartered in Caulfield, Australia.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?